These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11532347)

  • 1. Absence of major histocompatibility class II expression does not impair hematopoiesis in mice.
    Benito AI; Milner LA; Leisenring W; Deeg HJ; Woolfrey AE
    Exp Hematol; 2001 Sep; 29(9):1070-5. PubMed ID: 11532347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
    Broxmeyer HE; Cooper S; Hangoc G; Chang CH
    Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow cultures involves apoptosis and is prevented by c-kit ligand.
    Hong DS; Beckham C; Huss R; Lee JW; Hockenbery D; Ledbetter JA; Deeg HJ
    Blood; 1995 Nov; 86(9):3341-52. PubMed ID: 7579437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
    Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
    Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoimmunity and inflammation are independent of class II transactivator type PIV-dependent class II major histocompatibility complex expression in peripheral tissues during collagen-induced arthritis.
    Waldburger JM; Palmer G; Seemayer C; Lamacchia C; Finckh A; Christofilopoulos P; Baeten D; Reith W; Gabay C
    Arthritis Rheum; 2011 Nov; 63(11):3354-63. PubMed ID: 21739421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
    Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
    Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC class II transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity.
    Benasciutti E; Mariani E; Oliva L; Scolari M; Perilli E; Barras E; Milan E; Orfanelli U; Fazzalari NL; Campana L; Capobianco A; Otten L; Particelli F; Acha-Orbea H; Baruffaldi F; Faccio R; Sitia R; Reith W; Cenci S
    J Bone Miner Res; 2014 Feb; 29(2):290-303. PubMed ID: 24038328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
    Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
    J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged survival of class II transactivator-deficient cardiac allografts.
    June Brickey W; Felix NJ; Griffiths R; Zhang J; Wang B; Piskurich JF; Itoh-Lindstrom Y; Coffman TM; Ting JP
    Transplantation; 2002 Nov; 74(9):1341-8. PubMed ID: 12451276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class II transactivator knockdown limits major histocompatibility complex II expression, diminishes immune rejection, and improves survival of allogeneic bone marrow stem cells in the infarcted heart.
    Huang XP; Ludke A; Dhingra S; Guo J; Sun Z; Zhang L; Weisel RD; Li RK
    FASEB J; 2016 Sep; 30(9):3069-82. PubMed ID: 27221978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of adult human marrow hematopoietic progenitors highly enriched by two-color cell sorting with My10 and major histocompatibility class II monoclonal antibodies.
    Lu L; Walker D; Broxmeyer HE; Hoffman R; Hu W; Walker E
    J Immunol; 1987 Sep; 139(6):1823-9. PubMed ID: 3114377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of defective expression in MHC class II deficiency (bare lymphocyte syndrome) cells by retroviral transduction of CIITA.
    Bradley MB; Fernandez JM; Ungers G; Diaz-Barrientos T; Steimle V; Mach B; O'Reilly R; Lee JS
    J Immunol; 1997 Aug; 159(3):1086-95. PubMed ID: 9233601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of PU.1 in MHC Class II Expression via CIITA Transcription in Plasmacytoid Dendritic Cells.
    Miura R; Kasakura K; Nakano N; Hara M; Maeda K; Okumura K; Ogawa H; Yashiro T; Nishiyama C
    PLoS One; 2016; 11(4):e0154094. PubMed ID: 27105023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-B-deficient cells.
    Nagarajan UM; Peijnenburg A; Gobin SJ; Boss JM; van den elsen PJ
    J Immunol; 2000 Apr; 164(7):3666-74. PubMed ID: 10725724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of class II MHC antigens in subpopulations of human hematopoietic progenitor cells.
    Ottmann OG; Nocka KH; Moore MA; Pelus LM
    Leukemia; 1988 Oct; 2(10):677-86. PubMed ID: 3172844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of tumor necrosis factor on hematopoiesis seen in vitro are translated to increased numbers of both committed and multipotent progenitors in TNF-deficient mice.
    Drutskaya MS; Ortiz M; Liepinsh DJ; Kuprash DV; Nedospasov SA; Keller JR
    Exp Hematol; 2005 Nov; 33(11):1348-56. PubMed ID: 16263419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain.
    Itoh-Lindstrom Y; Piskurich JF; Felix NJ; Wang Y; Brickey WJ; Platt JL; Koller BH; Ting JP
    J Immunol; 1999 Sep; 163(5):2425-31. PubMed ID: 10452977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced production of IL-10 by dendritic cells deficient in CIITA.
    Yee CS; Yao Y; Xu Q; McCarthy B; Sun-Lin D; Tone M; Waldmann H; Chang CH
    J Immunol; 2005 Feb; 174(3):1222-9. PubMed ID: 15661876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression.
    Chang CH; Guerder S; Hong SC; van Ewijk W; Flavell RA
    Immunity; 1996 Feb; 4(2):167-78. PubMed ID: 8624807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class II transactivator (CIITA) promoter methylation does not correlate with silencing of CIITA transcription in trophoblasts.
    Holtz R; Choi JC; Petroff MG; Piskurich JF; Murphy SP
    Biol Reprod; 2003 Sep; 69(3):915-24. PubMed ID: 12748124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.